Dr. Filip Surmont brings over 30 years of extensive experience in healthcare and pharmaceutical industries, including 18 years in leadership positions at multinational pharmaceutical companies and 16 years of clinical practice. A globally recognized leader in the field of cardiovascular, metabolic, and renal diseases, he previously held senior medical leadership positions at Wyeth, Pfizer, and AstraZeneca. He has led medical affairs across diverse regions—including emerging markets, Latin America, Europe, the U.S., and China—successfully building high-performance teams and driving large-scale, guideline-level clinical practice transformations within complex global healthcare systems.
Dr. Filip Surmont has contributed to the success of dapagliflozin as a blockbuster medication; led the “ACT on HF” project in China, enabling 200,000 heart failure patients to benefit from guideline-recommended standard of care; pioneered the Anti-Inflammatory Reliever (AIR) therapy strategy for asthma, impacting approximately 50 million patients worldwide and driving updates to international treatment guidelines. As a distinguished scientist, Dr. Surmont has authored numerous peer-reviewed articles in elite medical journals, including The Lancet Diabetes, Endocrinology and Journal of the American College of Cardiology. In his early professional career, Dr. Filip Surmontprovided medical services for Olympic-level athletes.
Dr. Filip Surmont holds an M.D. and a Master’s degree in Sports Medicine from Ghent University, Belgium.